NCT02251873CompletedPhase 1
An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules) 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Both Bid for 13.5 Days With Single Dose Didanosine 400 mg (Delayed Release Capsule EC Beadlets) in Healthy Volunteers
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 50
- Primary Endpoint
- (AUC 0-12) Area under the plasma concentration time curve from 0-12 hours
Study Overview
Brief Summary
Study to characterise the effects of concurrent tipranavir (TPV) and ritonavir (RTV) administration on the single dose pharmacokinetics of didanosine (ddI), to characterise the effects of single-dose ddI on the pharmacokinetics of TPV and RTV and to assess the short-term safety of this combination
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male or female subjects as determined by results of screening
- •Female subjects were not lactating and not of child bearing potential as defined by surgically sterile or post menopausal (no periods for at least 12 months and elevated follicle stimulating hormone (FSH) with low estradiol and no estrogen supplementation). Females were to use barrier contraception (e.g. condoms) for at least one month prior to administration of study medication, during the study and at least one month after release from the study. Women were to have negative pregnancy tests
- •Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- •Age >=18 and <=60 years
- •Body mass index (BMI) >=18.5 and <=29.9 kg/m2
Exclusion Criteria
- •Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- •History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders, including a clinical history of viral hepatitis, or serological evidence of active Hepatitis B, Hepatitis C, or HIV infection
- •History of orthostatic hypotension, fainting spells and blackouts
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator including study drugs
- •Intake of drugs with a long half-life (> 24 hours) or enzyme altering drug within 1 month prior to administration of study drugs
- •Use of any drugs that might have influenced the results of the trial within 10 days prior to administration or during the trial (in addition to specific medication prohibitions mentioned in exclusion criteria above)
- •Use of grapefruit or grapefruit juice, alcohol, green tea, methylxanthine-containing products or tobacco within one week of study drug administration
- •Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
- •Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on trial days
- •Alcohol abuse (> 60 g/day)
- •Drug abuse
- •Blood or plasma donation within 1 month prior to administration or during the trial
- •Excessive physical activities within 5 days prior to administration or during the trial
- •Following specific laboratory findings: activated partial thromboplastin time (aPTT), prothrombin time international normalised ratio (INR), aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl-transferase (GGT), amylase, lipase, or triglyceride above the normal range
- •Any other laboratory value outside the clinically accepted reference range and of clinical relevance
- •History of any familial bleeding disorder
- •Inability to swallow multiple large capsules
- •Inability to comply with dietary regimen of study centre
- •Inability to comply with investigator's instructions
Arms & Interventions
TPV + RTV (low dose)+ ddI
Experimental
Intervention: TPV + RTV (low dose) (Drug)
TPV + RTV (low dose)+ ddI
Experimental
Intervention: ddl (Drug)
TPV+ RTV (high dose)+ ddI
Experimental
Intervention: TPV + RTV (high dose) (Drug)
TPV+ RTV (high dose)+ ddI
Experimental
Intervention: ddl (Drug)
Outcomes
Primary Outcomes
(AUC 0-12) Area under the plasma concentration time curve from 0-12 hours
Time Frame: up to 12 hours after dose administration
Cmax (Maximum measured concentration of the analyte in plasma)
Time Frame: up to 12 hours after dose administration
(C6h) drug concentration in plasma at 6 hours after drug administration
Time Frame: up to 6 hours after dose administration
Cnh (plasma concentration n hours after drug administration)
Time Frame: up to 12 hours after dose administration
(C12h) drug concentration in plasma at 12 hours after drug administration
Time Frame: up to 12 hours after dose administration
Secondary Outcomes
- Cmax,ss (maximum plasma concentration at steady state)(up to 12 hours after dose administration)
- Tmax (time to the maximum plasma concentration)(up to 12 hours after dose administration)
- Number of subjects with abnormal changes in laboratory parameters(up to 40 days)
- MRT (mean residence time)(up to 12 hours after dose administration)
- CL/F (apparent oral clearance)(up to 12 hours after dose administration)
- Number of subjects with adverse events(up to 40 days)
- Vz/F (apparent volume of distribution)(up to 12 hours after dose administration)
- t½ (Terminal half-life of the analyte in plasma)(up to 12 hours after dose administration)
Investigators
Similar Trials
Terminated
Phase 1
Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult VolunteersHealthyNCT02245438Boehringer Ingelheim52
Completed
Phase 1
Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy VolunteersHealthyNCT02251145Boehringer Ingelheim49
Terminated
Phase 2
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.HIV InfectionsNCT00144105Boehringer Ingelheim562
Completed
Phase 1
Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult VolunteersHealthyNCT02253823Boehringer Ingelheim68
Completed
Phase 1
Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy VolunteersHealthyNCT02249416Boehringer Ingelheim60